What's Hot
View all perspectives
Richard Conway
1 year ago
Plasma MMPs and RA-ILD. Strong association MMPs 7 & 9 with prevalent RA-ILD. Abstr#0770 #ACR23 @RheumNow https://t.co/5qWeK3lAly https://t.co/SyZY2OhcbH
Aurelie Najm
1 year ago
2 yrs extension of DRESS-PS study
100+ pts w/ PsA and AxSPA
-70% LDA state in both Ctrl & Intervention gps
-strong recovery after relapse
No difference efficacy protocolized & routine care tapering but inferior TNFi use (52 vs. 77%) in Intervention gp
@RheumNow #ACR23 ABST0775 https://t.co/V2DqCjT0w3
Eric Dein
1 year ago
Abs#0608 #ACR23 @RheumNow
Cenerimod: sphigosine 1-phos (S1P) 1 receptor modulator for SLE
P2 CARE Study
51% of pts had high IFN1 sign., ass w/ high dsDNA
Cenerimod 4 mg: decreased dsDNA and IFN-a protein at 6 mo vs b/l
In high IFN pts, 4 mg Cen: decrease SLEDAI, SRI-4
Eric Dein
1 year ago
Abs#595 #ACR23 @RheumNow
R Furie on 4 yr TULIP-LTE pts with b/l renal involvement
33% on anifrolumab continued to wk 208 vs PBO 6%
Renal improvement at w208 in 9/10 pts, vs no avail PBO data
Conclusion: more Anifrolumab pts remained in study & reached SLEDAI-2K renal improvement
Richard Conway
1 year ago
Cowley et al @sharoncowley01 Subclinical GCA in 17.5% with new PMR. Males with higher ESR more likely to have subclinical GCA. Subclinical GCA more axillary artery. Abstr#0747 #ACR23 #ACRbest @RheumNow https://t.co/CghmX1TKpf https://t.co/MJawtslLud
Robert B Chao, MD
1 year ago
Phase 3 Study of IV Secukinumab for treatment of PsA - efficacious and safety profile similar to Subq version
~60% ACR 50 response maintained at week 52
2nd responses of MDA, PASI90, enthesitis, dactylitis resolution met
@RheumNow #ACR23 Abs#0776 https://t.co/jikWd4fnGm
ReumaJoven
1 year ago
Entrevista de @RheumNow a las doctoras Griselda Serna Peña y Diana Flores Gutierrez sobre su trabajo de Screening y salud secual en pacientes con enfermedades reumáticas
#ACR23 @SernaDra @ColMexReuma https://t.co/SyuFVXM9Sf
Dr. John Cush RheumNow
1 year ago
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty
TheDaoIndex KDAO2011
1 year ago
Reporting for @RheumNow! #ACR23 follow our coverage! @ACRheum @uptotate @Yuz6Yusof @ericdeinmd https://t.co/e4ShTzZhrE
Eric Dein
1 year ago
Upadacitinib on wearable device-measure activity
SELECT-AXIS 2
Abs#0530 #ACR23 @RheumNow
UPA had numerically higher mean daily step counts than PBO
11% improvement v PBO at wk 14 (diff of 345 steps/day)
Sedentary pts: 22% improvement in daily step count from b/l on UPA (4% PBO) https://t.co/Gq91TmvfZC
Poster Hall